Accreditation Information

In support of improving patient care, Creative Educational Concepts is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Medicine(ACCME)

CEC designates this live educational activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacy (ACPE)

This application-based activity is approved for 1.0 contact hour (.10 CEUs) of continuing pharmacy education credit (JA0007101-0000-18-009-L01-P).

Nursing (ANCC)

This activity is designated for 1.0 contact hour.

Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.

Physician Assistants (AAPA)

Creative Educational Concepts has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

Upon completion of a CE request form, statements of credit for physicians, physician assistants, and nurses will be issued within 30 business days. Pharmacy credit will be reported directly to the National Association of Boards of Pharmacy® (NABP®) CPE Monitor electronic CE tracking system.

Needs Statement

Our understanding of underlying genetic mechanisms that drive tumorigenesis has exponentially increased over the last several years. As a result, there has been an ever-growing shift in the treatment paradigm for various cancer types, which have focused on personalized and more targeted therapies based on tumor and patient molecular genetics. Poly ADP-ribose polymerase (PARP) inhibitors are an emerging class of oral agents that have demonstrated efficacy in the treatment of various cancers, with the most robust data seen primarily in ovarian and breast cancers. PARP inhibitors specifically target tumor cells that have deficiencies in the DNA damage repair (DDR) pathways, including tumors with BRCA1/2 and other DDR mutations. As relatively new agents in the oncology space, oncology professionals must be knowledgeable in the identification of patients who would benefit from the use of PARP inhibitors, the appropriate selection of a PARP inhibitor for individual patients, as well as the recognition and management of toxicities associated with these agents.

This initiative is targeted to oncologists, oncology residents/fellows, nurse practitioners, nurses, physician assistants, pharmacists, genetic counselors, and other members of the gynecologic/breast cancer patient care team. Attendees of this Grand Rounds series will gain an appreciation of the latest clinical and scientific advances in targeting DNA damage response (DDR), including updates on the current and emerging prospects of poly-ADP ribose polymerase (PARP) inhibitors in gynecologic and breast cancers, the most up-to-date guidelines on genetic testing and counseling for DDR mutations (e.g., BRCA), as well as case-based strategies members of the oncology patient care team can employ to improve patient outcomes and adherence to therapy.

 

Objectives

  1. Analyze the main signaling pathways and key mechanisms in DNA damage repair and how deficiencies in these pathways can lead to tumor proliferation and growth.
  2. Explore evolving data regarding the efficacy and adverse event profiles of PARP inhibitors currently approved and in clinical development for patients with ovarian and breast cancers.
  3. Appraise the importance of recommended genetic testing and counseling in patients with possible deleterious mutations in the DNA damage response pathway and its implications on patient treatment and management.
  4. Using a case-based approach, discuss challenging questions regarding PARP inhibitors and examine ways that members of the oncology care team can optimize therapy, enhance safety, anticipate adverse effects, and improve adherence.

Target Audience

Oncologists, oncology residents/fellows, nurse practitioners, nurses, physician assistants, pharmacists, genetic counselors, and other members of the oncology patient care team.

Faculty Disclosure

Planner and Faculty Disclosures
In accordance with the Food and Drug Administration, the speakers have disclosed that there is the potential for discussions concerning off-label uses of a commercial product/device during this educational activity. 

Any person who may contribute to the content of this continuing education activity must disclose relevant relationships (and any known relationships of their spouse/partner) with commercial interests whose products or services are discussed in educational presentations. A commercial interest is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Relevant relationships include receiving from a commercial interest research grants, consultant fees, travel, other benefits, or having a self-managed equity interest in a company.

Disclosure of a relationship is not intended to suggest or condone any bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

Planners
Vanessa Carranza, PharmD—has no relevant financial relationships to disclose in relation to the content of this activity.

Jessica Hall—has no relevant financial relationships to disclose in relation to the content of this activity.

Ursula Matulonis, MD—has disclosed that she is a consultant for 2X Oncology, FUJIFILM, Geneos, Immunogen, Merck, Mersana Therapeutics, Inc., and Myriad.

Melinda Telli, MD—has disclosed that she is a consultant for Merck, Pfizer and TESARO, Inc. Her institution receives grant/research support from Abbvie, Pfizer and TESARO, Inc.

Presenters

Floor J. Backes, MD—has disclosed that she is a consultant for Clovis and TESARO, Inc. She receives grant/research support from Clovis.

Beth Y. Karlan—has disclosed that she is a consultant and on the speakers’ bureau for Invitae. She receives grant/research support from AstraZeneca and TESARO, Inc.

Ursula Matulonis, MD—has disclosed that she is a consultant for 2X Oncology, FUJIFILM, Geneos, Immunogen, Merck, Mersana, and Myriad.

Bradley J. Monk, MD, FACS, FACOG—has  disclosed that he is a consultant for Abbvie, Advaxis, Amgen, AstraZeneca, Biodesix, Clovis, Genmab, Gradalis, ImmunoGen, Immunomedics, Incyte, Janssen/Johnson&Johnson, Mateon, Merck, Myriad, Perthera, Pfizer, Precison Oncology, Puma, Roche/Genentech, Samumed, Takeda, TESARO, Inc., and VBL. He also is a member of the speakers’ bureaus for AstraZeneca, Clovis, Janssen/Johnson&Johnson, Roche/Genentech, and TESARO, Inc.

Pamela Munster, MD—disclosures to come.

Bobbie J. Rimel, MD-has disclosed that she is a consultant for AstraZeneca, Clovis, Genentech, and TESARO, Inc. 

Angeles Alvarez Secord, MD—has disclosed that she is a consultant for Alexion, Aravive, AstraZeneca, Clovis and Janssen/Johnson&Johnson. She also receives grant/research support from AbbVie, Amgen, Astellas Pharma Inc., and Astex.

Melinda Telli, MD—has disclosed that she is a consultant for Merck, Pfizer and TESARO, Inc. Her institution receives grant/research support from Abbvie, Pfizer and TESARO, Inc.

Andrea E. Wahner Hendrickson, MD—has no relevant financial relationships to disclose in relation to the content of this activity.

Robert M. Wenham, MD, MS, FACOG, FACS—has disclosed that he is a consultant for Clovis, Genentech, Mersana Therapeutics, Inc., and TESARO, Inc. He receives grant/research support from Merck. He also is a member of the speakers’ bureaus for Clovis, Genentech, and TESARO, Inc.

Shannon N. Westin, MD, MPH—has no relevant financial relationships to disclose in relation to the content of this activity.

Reviewers

Gabriela Lacatus, RN, BSN, OCN, PhD—has no relevant financial relationships to disclose in relation to the content of this activity.

Megan May, PharmD, BCOP—has no relevant financial relationships to disclose in relation to the content of this activity.

Shannon N. Westin, MD, MPH—has no relevant financial relationships to disclose in relation to the content of this activity.